glp-1/gcgr dual agonist Effects, working principles and target tissues of agonists Evaluation of biased agonism mediated

But those are not yet available, making oral semaglutide the current leader in needle-free GLP-1 therapy

GLP-1RAs contribute to improved glycemic control by lowering glycated hemoglobin (HbA1c) and promoting weight loss without causing hypoglycemia, a notable advantage over sulfonylureas and meglitinides

Four centers in the USA enrolled adults with T2S, a glycated hemoglobin A1c (HbA1c) score of 7.0-10.5%, and a body mass index (BMI) of 23-50 kg/m2

The most well-established microvascular diseases and disorders include diabetic microvascular complications, small cerebral vessel disease, renal microvascular disease, pulmonary microvascular disease, systemic autoimmune microvascular disorders, and hereditary microangiopathies [155,156,157,158]

So far, studies on these new, multi-agonist drugs suggest that activating multiple receptors may lead to greater weight loss than GLP-1 alone

However, dihydroferulic acid, a microbial metabolite of ferulic acid, markedly stimulated GLP-1 production in L-cells, highlighting a role of gut-mediated metabolism in YMs incretin effects